Business Context and Reporting Period
This Form 8-K Current Report was filed by Faraday Future Intelligent Electric Inc. on September 30, 2025. The report addresses a specific corporate event under Item 8.01 (Other Events) rather than providing a comprehensive financial performance review for a fiscal period.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the announcement of a strategic investment transaction.
Material Changes and Events
- Investment Closing: On September 30, 2025, the company announced the closing of its investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN).
- Securities Information: The company's Class A common stock trades under the symbol FFAI on The Nasdaq Stock Market LLC. Redeemable warrants (symbol FFAIW) are also registered, with an exercise price of $110,400.00 per share.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors related to the investment. The document includes a standard disclaimer stating that the information furnished in this report is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific terms and financial impact of the investment in Qualigen Therapeutics, Inc. by reviewing the attached Press Release (Exhibit 99.1).
- Confirm the current cash position and liquidity status of Faraday Future to assess the impact of this investment on ongoing operations.
- Review the company's most recent 10-K or 10-Q filings for updated revenue, debt, and burn rate metrics, as this 8-K does not contain them.